NEWS
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
Vaccinex announced the completion of the last patient visit in its Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's Disease (AD). The database lock is expected in June, with key outcomes to be reported in July.
Pepinemab targets astrocyte reactivity and neuroinflammation, believed to accelerate AD progression. Key endpoints include safety, tolerability, brain metabolic activity, and biomarkers like GFAP and p-tau 217. The study also uses cognitive scales to assess treatment effects on cognitive decline.
Funded partly by $4.75 million from the Alzheimer’s Drug Discovery Foundation and a $0.75 million grant from the Alzheimer’s Association, pepinemab has shown potential to offer alternative or complementary treatment to existing anti-Aβ therapies.
Pepinemab targets astrocyte reactivity and neuroinflammation, believed to accelerate AD progression. Key endpoints include safety, tolerability, brain metabolic activity, and biomarkers like GFAP and p-tau 217. The study also uses cognitive scales to assess treatment effects on cognitive decline.
Funded partly by $4.75 million from the Alzheimer’s Drug Discovery Foundation and a $0.75 million grant from the Alzheimer’s Association, pepinemab has shown potential to offer alternative or complementary treatment to existing anti-Aβ therapies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1065Followers
68Following
7319Visitors
Follow